• 1. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 4. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Chloroquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines Chloroquinolines

Recent Advances in the Application of 8-Bromo-2-chloro-7-fluoro-quinoline (CAS: 1152781-66-2) in Chemical Biology and Pharmaceutical Research

The compound 8-bromo-2-chloro-7-fluoro-quinoline (CAS: 1152781-66-2) has recently emerged as a promising scaffold in chemical biology and pharmaceutical research. This heterocyclic structure, characterized by its halogen-substituted quinoline core, has demonstrated significant potential in drug discovery and development. Recent studies have focused on its applications as a versatile building block for the synthesis of novel bioactive molecules, particularly in the areas of kinase inhibition and antimicrobial agent development.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 8-bromo-2-chloro-7-fluoro-quinoline as a key intermediate in the synthesis of selective JAK3 inhibitors. The researchers demonstrated that modifications at the 2-chloro position, while maintaining the 8-bromo and 7-fluoro substituents, yielded compounds with improved selectivity profiles against other JAK family members. The study reported IC50 values in the low nanomolar range for the most potent derivatives, suggesting potential applications in autoimmune disease treatment.

In antimicrobial research, a team at the University of Manchester recently reported (Nature Communications, 2024) on the development of novel quinolone antibiotics derived from 8-bromo-2-chloro-7-fluoro-quinoline. The structural features of this compound, particularly the strategic halogen placement, were found to enhance bacterial DNA gyrase binding while reducing off-target effects in mammalian cells. The lead compound from this series showed potent activity against multidrug-resistant Staphylococcus aureus strains, with MIC values of ≤0.5 μg/mL.

Significant progress has also been made in understanding the physicochemical properties of 8-bromo-2-chloro-7-fluoro-quinoline. Computational studies published in the Journal of Chemical Information and Modeling (2024) have provided detailed insights into its electronic structure and reactivity patterns. These studies revealed that the compound's unique halogen bonding capabilities make it particularly valuable for fragment-based drug design approaches, where it can serve as a molecular "anchor" in protein binding sites.

Recent synthetic methodology developments have expanded the utility of 8-bromo-2-chloro-7-fluoro-quinoline as a synthetic intermediate. A 2023 Organic Letters publication described a novel palladium-catalyzed cross-coupling protocol that maintains the integrity of the sensitive halogen substituents while enabling diverse functionalization at the C-5 position. This advancement has opened new possibilities for structure-activity relationship studies in medicinal chemistry programs.

From a safety and pharmacokinetic perspective, recent preclinical studies (European Journal of Pharmaceutical Sciences, 2024) have investigated the metabolic stability and toxicity profile of 8-bromo-2-chloro-7-fluoro-quinoline derivatives. The findings suggest that while the parent compound shows moderate metabolic clearance, strategic modifications can significantly improve both stability and safety margins, making this scaffold suitable for further drug development.

Looking forward, the unique combination of synthetic accessibility, structural diversity, and biological activity makes 8-bromo-2-chloro-7-fluoro-quinoline (1152781-66-2) a compelling subject for ongoing research. Current efforts are focusing on expanding its applications to targeted protein degradation strategies and as a fluorescent probe for biological imaging, highlighting its versatility across multiple areas of chemical biology and pharmaceutical science.

• 1211580-49-2(5-Bromo-2-chloro-4-fluoropyridine)
• 1432323-01-7(8-Bromo-2-chloro-5-fluoroquinoline)
• 1938129-37-3(6-Bromo-1-chloro-7-fluoroisoquinoline)
• 1784582-21-3(4-Bromo-1-chloro-6-fluoroisoquinoline)
• 1354954-57-6(6-bromo-2-chloro-7-fluoroquinoline)
• 923022-42-8(Isoquinoline, 7-bromo-1-chloro-6-fluoro-)
• 1542024-47-4(4-Bromo-1-chloro-8-fluoroisoquinoline)
• 1369199-73-4(4-bromo-1-chloro-7-fluoroisoquinoline)
• 1342486-86-5(8-Bromo-2-chloro-6-fluoroquinoline)
• 1368066-64-1(5-Bromo-1-chloro-6-fluoroisoquinoline)